Figure 1. Flow of Participants in the KARDIA-1 Trial of Subcutaneous Zilebesiran for Hypertension.

^aA patient could have multiple reasons for screen failure and was counted for each reason separately.

^bRandomization was stratified by race (Black or other) and baseline mean 24-hour systolic blood pressure (<145 or ≥145 mm Hg).

^cPatients withdrew consent because of work-related reasons (n = 4), distance to the site (n = 3), no disclosed reason (n = 2), principal care clinician’s advice (n = 2), time constraints (n = 1), the study not being worth their time (n = 1), personal reasons (n = 1), unwillingness to adhere to ambulatory blood pressure monitoring requirements (n = 1), and adverse events (n = 1).

^dPatient was incarcerated during study.

^ePatients enrolled at sites in Ukraine (n = 16) were excluded after randomization because war prevented continued data collection.

^fPrimary analysis was carried out in the full analysis set, which included all randomized patients who received any amount of study drug.